drugset / Trial / NCT02568423
A Study of Mirikizumab (LY3074828) in Healthy Participants
RandomizedParallel-groupDouble-blindBasic science
Summary
The main purpose of this study is to explore the safety and tolerability of mirikizumab in healthy Japanese and Caucasian participants. The study will also estimate how much mirikizumab gets into the blood stream and how long it takes the body to remove it. The study is expected to last about 16 weeks for each participant.
Timeline
- Start
- 2015-12-02
- Primary completion
- 2018-07-16
- Completion
- 2018-10-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirikizumab | Monoclonal antibody | 60 mg | Intravenous |
| Subject | Mirikizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Mirikizumab | Monoclonal antibody | 600 mg | Intravenous |
| Subject | Mirikizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Mirikizumab | Monoclonal antibody | 2400 mg | Intravenous |
Indications
No indication recorded.